grekovВестник хирургии имени И.И. ГрековаGrekov's Bulletin of Surgery0042-46252686-7370Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation, FSBEI HE I.P.Pavlov SPbSMU MOH Russia10.24884/0042-4625-2018-177-5-105-107grekov-1067Research ArticleОБЗОРЫREVIEWSИммуносупрессия при сепсисе и возможности ее коррекцииImmunosuppression in sepsis and possibility of its correctionКиселевскийМ. В.KiselevskiiM. V.

Киселевский Михаил Валентинович - доктор медицинских наук, профессор, заведующий лабораторией клеточного иммунитета.

115478, Москва, Каширское шоссе, д. 23

Moscow

kisele@inbox.ruСитдиковаС. М.SitdikovaS. M.

Ситдикова Сурия Мансуровна - кандидат биологических наук, старший научный сотрудник лаборатории клеточного иммунитета.

115478, Москва, Каширское шоссе, д. 23

Moscow

suriyasitdikova@yandex.ruАбдуллаевА. Г.AbdullaevA. G.

Абдуллаев Амир Гусейнович - доктор медицинских наук, ведущий научный сотрудник торакального отделения.

115478, Москва, Каширское шоссе, д. 23

Moscow

amirdo@mail.ruШляпниковС. А.ShlyapnikovS. A.

Шляпников Сергей Алексеевич - доктор медицинских наук, профессор, руководитель «Городского центра по лечению тяжелого сепсиса», заведующий кафедрой хирургических инфекций СЗГМУ им. И. И. Мечникова.

192242, Санкт-Петербург, ул. Будапештская, д. 3, лит. А

St. Petersburg

shlyapnikov@emergency.spb.ruЧикилеваИ. О.ChikilevaI. O.

Чикилева Ирина Олеговна - канд. биол. наук, научный сотрудник лаборатории клеточного иммунитета.

115478, Москва, Каширское шоссе, д. 23

Moscow

irinatchikileva@mail.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution «N.N. Blokhin National Medical Research Centre of Oncology», of the Ministry of Healthcare of the Russian FederationRussian FederationГосударственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи имени И.И. ДжанелидзеРоссияFederal State Budgetary Institution Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency MedicineRussian Federation2018281020181775105107Copyright © Киселевский М.В., Ситдикова С.М., Абдуллаев А.Г., Шляпников С.А., Чикилева И.О., 20182018Киселевский М.В., Ситдикова С.М., Абдуллаев А.Г., Шляпников С.А., Чикилева И.О.Kiselevskii M.V., Sitdikova S.M., Abdullaev A.G., Shlyapnikov S.A., Chikileva I.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vestnik-grekova.ru/jour/article/view/1067

Обзор литературы посвящен иммуносупрессии при сепсисе и возможностям ее коррекции.

Literature review is devoted to immunosuppression in sepsis and possibilities of its correction.

сепсисиммуносупрессияантибиотикотерапияиммунотерапияsepsisimmunosuppressionantibiotic therapyimmunotherapyReferencesTargeting Immune Cell Checkpoints during Sepsis / N. K. Patil, Y. Guo, L. Luan, E. R. Sherwood // Int. J. Mol. Sci. 2017. Vol. 18, № 11. P. 2413.Targeting Immune Cell Checkpoints during Sepsis / N. K. Patil, Y. Guo, L. Luan, E. R. Sherwood // Int. J. Mol. Sci. 2017. Vol. 18, № 11. P. 2413.Fleischmann C., Scherag A., Adhikari N. K. et al. International Forum of Acute Care Team. Assessment of Global incidence and mortality of hospital-treated sepsis. Current estimates and limitations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193. P. 259–272.Fleischmann C., Scherag A., Adhikari N. K. et al. International Forum of Acute Care Team. Assessment of Global incidence and mortality of hospital-treated sepsis. Current estimates and limitations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193. P. 259–272.Singer M., Deutschman C. S., Seymour C. W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. 2016. Vol. 315. P. 801–810.Singer M., Deutschman C. S., Seymour C. W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. 2016. Vol. 315. P. 801–810.Hotchkiss R. S., Monneret G., Payen D. Immunosuppression in sepsis : a novel understanding of the disorder and a new therapeutic approach // Lancet Infect Dis. 2013. Vol. 13, № 3. P. 260–268.Hotchkiss R. S., Monneret G., Payen D. Immunosuppression in sepsis : a novel understanding of the disorder and a new therapeutic approach // Lancet Infect Dis. 2013. Vol. 13, № 3. P. 260–268.Boomer J. S., Green J. M., Hotchkiss R. S. The changing immune system in sepsis : is individualized immuno-modulatory therapy the answer? // Virulence. 2014. Vol. 5, № 1. P. 45–56.Boomer J. S., Green J. M., Hotchkiss R. S. The changing immune system in sepsis : is individualized immuno-modulatory therapy the answer? // Virulence. 2014. Vol. 5, № 1. P. 45–56.Gentile L. F., Cuenca A. G., Efron P. A. et al. Persistent inflammation and immunosuppression : A common syndrome and new horizon for surgical intensive care // J. Trauma Acute Care Surg. 2012. Vol. 72. P. 1491–1501.Gentile L. F., Cuenca A. G., Efron P. A. et al. Persistent inflammation and immunosuppression : A common syndrome and new horizon for surgical intensive care // J. Trauma Acute Care Surg. 2012. Vol. 72. P. 1491–1501.Hotchkiss R. S., Karl I. E. The pathophysiology and treatment of sepsis // N. Engl. J. Med. 2003. Vol. 348, № 2. P. 138–150.Hotchkiss R. S., Karl I. E. The pathophysiology and treatment of sepsis // N. Engl. J. Med. 2003. Vol. 348, № 2. P. 138–150.Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lancet Infect Dis. 2012. Vol. 12. № 7. P. 503–505.Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lancet Infect Dis. 2012. Vol. 12. № 7. P. 503–505.Benchmarking the incidence and mortality of severe sepsis in the United States / D. F. Gaieski, J. M. Edwards, M. J. Kallan, B. G. Carr // Critical care medicine. 2013. Vol. 41, № 5. P. 1167–1174.Benchmarking the incidence and mortality of severe sepsis in the United States / D. F. Gaieski, J. M. Edwards, M. J. Kallan, B. G. Carr // Critical care medicine. 2013. Vol. 41, № 5. P. 1167–1174.Delano M. J., Ward P. A. Sepsis-induced immune dysfunction: Can immune therapies reduce mortality? // J. Clin. Investig. 2016. Vol. 126. P. 23–31.Delano M. J., Ward P. A. Sepsis-induced immune dysfunction: Can immune therapies reduce mortality? // J. Clin. Investig. 2016. Vol. 126. P. 23–31.Walton A. H., Muenzer J. T., Rasche D. et al. Reactivation of multiple viruses in patients with sepsis // PLoS ONE. 2014. Vol. 9. P. e98819.Walton A. H., Muenzer J. T., Rasche D. et al. Reactivation of multiple viruses in patients with sepsis // PLoS ONE. 2014. Vol. 9. P. e98819.Hotchkiss R. S., Sherwood E. R. Immunology. Getting sepsis therapy right // Science. 2015. Vol. 347. P. 1201–1202.Hotchkiss R. S., Sherwood E. R. Immunology. Getting sepsis therapy right // Science. 2015. Vol. 347. P. 1201–1202.ICU-acquired immunosuppression and the risk for secondary fungal infections / G. Monneret, F. Venet, B. J. Kullberg, M. G. Netea // Med. Mycol. 2011. Vol. 49, Suppl. 1. P. S17–S23.ICU-acquired immunosuppression and the risk for secondary fungal infections / G. Monneret, F. Venet, B. J. Kullberg, M. G. Netea // Med. Mycol. 2011. Vol. 49, Suppl. 1. P. S17–S23.Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.Boomer J. S., To K., Chang K. C. et al. Immunosuppression in patients who die of sepsis and multiple organ failure // Jama. 2011. Vol. 306, № 23. P. 2594–2605.Boomer J. S., To K., Chang K. C. et al. Immunosuppression in patients who die of sepsis and multiple organ failure // Jama. 2011. Vol. 306, № 23. P. 2594–2605.Ayala A., Herdon C. D., Lehman D. L. et al. The induction of accelerated thymic programmed cell death during polymicrobial sepsis : control by corticosteroids but not tumor necrosis factor // Shock. 1995. Vol. 3, № 4. P. 259–267.Ayala A., Herdon C. D., Lehman D. L. et al. The induction of accelerated thymic programmed cell death during polymicrobial sepsis : control by corticosteroids but not tumor necrosis factor // Shock. 1995. Vol. 3, № 4. P. 259–267.Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lan cet Infect Dis. 2012. Vol. 12, № 7. P. 503–505.Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lan cet Infect Dis. 2012. Vol. 12, № 7. P. 503–505.Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo / M. A. Williams, S. Withington, A. C. Newland, S. M. Kelsey // The Journal of infectious diseases. 1998. Vol. 178, № 5. Р. 1421–1433.Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo / M. A. Williams, S. Withington, A. C. Newland, S. M. Kelsey // The Journal of infectious diseases. 1998. Vol. 178, № 5. Р. 1421–1433.Fan X., Liu Z., Jin H. et al. Alterations of dendritic cells in sepsis : featured role in immunoparalysis // BioMed Research International. 2015. Vol. 2015. ID 903720.Fan X., Liu Z., Jin H. et al. Alterations of dendritic cells in sepsis : featured role in immunoparalysis // BioMed Research International. 2015. Vol. 2015. ID 903720.Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.Venet F., Chung C. S., Kherouf H. et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (−)) contribute to lymphocyte anergy in septic shock patients // Intensive care medicine. 2009. Vol. 35, № 4. P. 678–686.Venet F., Chung C. S., Kherouf H. et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (−)) contribute to lymphocyte anergy in septic shock patients // Intensive care medicine. 2009. Vol. 35, № 4. P. 678–686.Drewry A. M., Samra N., Skrupky L. P. et al. Persistent Lymphopenia after Diagnosis of Sepsis Predicts Mortality // Shock. 2014. Vol. 42, № 5. Р. 383–391.Drewry A. M., Samra N., Skrupky L. P. et al. Persistent Lymphopenia after Diagnosis of Sepsis Predicts Mortality // Shock. 2014. Vol. 42, № 5. Р. 383–391.Nalos M., Santner-Nanan B., Parnell G. et al. Immune effects of interferon gamma in persistent staphylococcal sepsis // Am. J. Respir. Crit. Care Med. 2012. Vol. 185, № 1. P. 110–112.Nalos M., Santner-Nanan B., Parnell G. et al. Immune effects of interferon gamma in persistent staphylococcal sepsis // Am. J. Respir. Crit. Care Med. 2012. Vol. 185, № 1. P. 110–112.Levy Y., Sereti I., Tambussi G. et al. Effects of recombinant human inter leukin 7 on T-cell recovery thymic output in HIV-infected patients re cei ving antiretroviral therapy : results of a phase I/IIa randomized placebo-controlled multicenter study // Clin. Infect Dis. 2012. Vol. 55, № 2. P. 291–300.Levy Y., Sereti I., Tambussi G. et al. Effects of recombinant human inter leukin 7 on T-cell recovery thymic output in HIV-infected patients re cei ving antiretroviral therapy : results of a phase I/IIa randomized placebo-controlled multicenter study // Clin. Infect Dis. 2012. Vol. 55, № 2. P. 291–300.Guo Y., Luan L., Rabacal W. et al. IL-15 Superagonist-Mediated Immunotoxicity : Role of NK Cells and IFN-gamma // Journal of immunology. 2015. Vol. 195, № 5. P. 2353–2364.Guo Y., Luan L., Rabacal W. et al. IL-15 Superagonist-Mediated Immunotoxicity : Role of NK Cells and IFN-gamma // Journal of immunology. 2015. Vol. 195, № 5. P. 2353–2364.Conlon K. C., Lugli E., Welles H. C. et al. Redistribution hyperproliferation activation of natural killer cells CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer // Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Vol. 33, № 1. P. 74–78.Conlon K. C., Lugli E., Welles H. C. et al. Redistribution hyperproliferation activation of natural killer cells CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer // Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Vol. 33, № 1. P. 74–78.Анисимов А. Ю. Иммунотерапия ронколейкином в комплексном лечении больных абдоминальным сепсисом / Казан. гос. мед. акад. Минздрава России. Казань, 2004. 28 с.Anisimov A. Yu. Immunoterapiya ronkolejkinom v kompleksnom lechenii bol’nyh abdominal’nym sepsisom / Kazanskaya gosudarstvennaya medicinskaya akademiya Minzdra va Rossii. Kazan’, 2004. 28 p.Лебедев В. Ф., Гаврилин С. В., Козлов В. К. Иммунопрофилактика и опережающая терапия посттравматического сепсиса дрожжевым рекомбинантным интерлейкином-2 // Цитокины и воспаление. 2002. Т. 1, № 2. С. 46–47.Lebedev V. F., Gavrilin S. V., Kozlov V. K. Immunoprofilaktika i operezhayushchaya terapiya posttravmaticheskogo sepsisa drozhzhevym rekombinantnym interlejkinom-2 // Citokiny i vospalenie. 2002. Vol. 1, № 2. P. 46–47.Опыт применения Ронколейкина в раннем периоде травматической болезни / М. Ф. Лебедев, С. В. Гаврилин, В. К. Козлов, В. Н. Егорова // Terra Medica. 2001. № 3. С. 35–37.Lebedev M. F., Gavrilin S. V., Kozlov V. K., Egorova V. N. Opyt primeneniya Ronkolejkina v rannem periode travmaticheskoj bolezni // Terra Medica. 2001. № 3. P. 35–37.Гаврилин С. В., Козлов В. К., Лебедев В. Ф. Иммунопатогенез тяжелых ранений и травм : возможности иммунокоррекции // Вестн. хир. им. И. И. Грекова. 2002. № 4. С. 85–90.Gavrilin S. V., Kozlov V. K., Lebedev V. F. Immunopatogenez tyazhelyh ranenij i travm : vozmozhnosti immunokorrekcii // Vestnik khirurgii im. I. I. Grekova. 2002. № 4. P. 85–90.Patera A. C., Drewry A. M., Chang K. et al. Frontline Science : Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 // J. Leukoc. Biol. 2016. Vol. 100. P. 1239–1254.Patera A. C., Drewry A. M., Chang K. et al. Frontline Science : Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 // J. Leukoc. Biol. 2016. Vol. 100. P. 1239–1254.

The authors declare that there are no conflicts of interest present.